The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
The study authors described the clinical benefit rate seen as similar to that reported in clinical trials.
Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.
Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.
After colorectal cancer screening guidelines lowered the age at which to start screening to age 45 years, increased screening rates followed among younger individuals.
Without a “clear” overall survival benefit from maintenance therapy, observation remains an option for patients with metastatic colorectal cancer.
NCI-MATCH trial identified additional patients who may benefit from nivolumab.
Increase in screening rates in quarters 3, 4 of 2018 versus quarter 1; no change for people in their 50s
Researchers assessed the relationship between gout and colorectal cancer in a cohort of veterans.
Aspirin use three or more times per week tied to reduced all-cause, cancer, GI cancer, CRC mortality.
A biosimilar is a biological product that is approved based on data demonstrating high similarity to an FDA-approved biological product (reference product).
Genetic testing provided important information beyond personal and family history.
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity.
A convolutional neural networks-based approach to the analysis of images of histopathologic slides does not require prior slide annotation by a pathologist.
Patterns of genetic alterations could guide management.
In this study, researchers identified 8 common themes related to challenges patients experience with ostomy self-management.
Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
In this study, there was no correlation between the presence of MET gene amplification and the presence of MET protein overexpression.
A retrospective chart review conducted after implementing an ERAS program demonstrated that improved patient education led to less use of opioids in the immediate postoperative period.